Burlington, North Carolina

Former Labcorp Technical Director of R&D, Brian Krueger Joins Premier Medical Laboratory Services as New Chief Scientific Officer

Retrieved on: 
Tuesday, July 27, 2021
Burlington, North Carolina, LabCorp, Medical laboratory, Natural sciences, Medicine, Academic disciplines

GREENVILLE, S.C., July 27, 2021 /PRNewswire/ -- Brian Krueger, former Technical Director of R&D at Labcorp, joined the Premier Medical Laboratory Services (PMLS) team as the new Chief Scientific Officer.

Key Points: 
  • GREENVILLE, S.C., July 27, 2021 /PRNewswire/ -- Brian Krueger, former Technical Director of R&D at Labcorp, joined the Premier Medical Laboratory Services (PMLS) team as the new Chief Scientific Officer.
  • "We are completely honored for Brian to join the team," said Kevin Murdock, CEO of Premier Medical Laboratory Services.
  • "His experience and knowledge of the field is extremely valuable in propelling us forward to fulfill our capabilities as a laboratory.
  • As Chief Scientific Officer at Premier Medical Laboratory Services Dr. Krueger oversees clinical assay development and ensures PMLS continues to maintain the highest of scientific standards.

Medical Home Network, Labcorp Collaboration Harnesses Data Analytics to Provide More Comprehensive Patient Health Picture

Retrieved on: 
Thursday, July 8, 2021
Burlington, North Carolina, LabCorp, Health informatics

Additionally, the MHNConnect data engine will verify that lab analysis of a specimen is complete and alert the care team to abnormal results.

Key Points: 
  • Additionally, the MHNConnect data engine will verify that lab analysis of a specimen is complete and alert the care team to abnormal results.
  • "We know that lab test results influence the majority of clinical decisions," said Dr. Jay Bhatt, MHN's chief clinical product officer and medical director.
  • Lab results bring immediate intelligence to an overall patient health picture, which the MHNConnect platform draws from claims and electronic health records.
  • "Labcorp and MHN share a common vision to improve care and build healthier communities," said Chris Garcia, M.D., medical director of clinical informatics at Labcorp.

Labcorp to Announce Second Quarter Financial Results on July 29, 2021

Retrieved on: 
Friday, July 2, 2021
Health, Medical devices, Hospitals, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Finance, Money, Burlington, North Carolina, LabCorp, Corporate finance, Stock market, Economy, LH, New York Stock Exchange, Investor relations

Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021.

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021.
  • The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website .
  • In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website .
  • The webcast of the conference call will be archived and accessible through July 15, 2022, on the Labcorp Investor Relations website .

Labcorp And OmniSeq Launch INSIGHT℠, Next-Generation Sequencing Platform to Advance Precision Oncology

Retrieved on: 
Monday, June 14, 2021
Burlington, North Carolina, LabCorp, Covance, Precision medicine, Dynacare, Oncology, Life sciences, Articles, Industry economics)

The test is designed to advance precision oncology and improve patient outcomes, as part of Labcorp's commitment to empower better health decisions for patients through the addition of cutting-edge diagnostic tools in precision medicine.

Key Points: 
  • The test is designed to advance precision oncology and improve patient outcomes, as part of Labcorp's commitment to empower better health decisions for patients through the addition of cutting-edge diagnostic tools in precision medicine.
  • OmniSeq INSIGHT is available to U.S.-based clinicians exclusively through Labcorp, and across Canada through Dynacare, a Labcorp company.
  • "We are excited to advance our partnership with Labcorp, continuing to provide increased access to oncology care for patients leveraging Labcorp's extensive footprint and oncology experience," said Margot Schoenborn, CEO of OmniSeq.
  • Learn about Covance by Labcorp at www.Covance.com , and Labcorp at www.Labcorp.com , or follow us on LinkedIn and Twitter @Labcorp.

Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits Now Available Nationwide at Walgreens and Through On-Demand Delivery

Retrieved on: 
Tuesday, June 8, 2021
Women, Seniors, Retail, Teens, Parenting, Pharmaceutical, MEN, Children, Convenience store, Family, Infectious diseases, Online Retail, Consumer, Medical Supplies, General Health, Biotechnology, Other Retail, Health, Life sciences, Articles, Burlington, North Carolina, LabCorp, Mobile phones, Google Pixel, Walgreens, Instacart, Pixel, DoorDash, Polymerase chain reaction, LH

Labcorp (NYSE: LH), a leading global life sciences company today announced that Pixel by Labcorp COVID-19 PCR Test Home Collection Kits are now in 6,000 Walgreens stores nationwide and through Walgreens collaborations with on-demand delivery services DoorDash and Instacart.

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company today announced that Pixel by Labcorp COVID-19 PCR Test Home Collection Kits are now in 6,000 Walgreens stores nationwide and through Walgreens collaborations with on-demand delivery services DoorDash and Instacart.
  • Customers will be able to purchase the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit at the pharmacy counter without a prescription, or they can order it for delivery through DoorDash and Instacart.
  • Additionally, the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit is available on Pixel by Labcorp and Walgreens Find Care , a digital health platform available on the Walgreens app and at Walgreens.com.
  • As recently announced , parents and guardians can request the kits for use with children and adolescents ages 2-17 through the Pixel by Labcorp website.

908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer of Labcorp Diagnostics, to its Board of Directors

Retrieved on: 
Tuesday, June 8, 2021
Biotechnology, Consumer electronics, Technology, Health, Other Science, Other Technology, Medical devices, Research, Software, Science, Hardware, Burlington, North Carolina, LabCorp

908 Devices (NASDAQ: MASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, to serve on its Board of Directors effective immediately.

Key Points: 
  • 908 Devices (NASDAQ: MASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, to serve on its Board of Directors effective immediately.
  • Marcia has a proven track record and a broad range of experience from diagnostics, to drug development and to forensics.
  • I look forward to collaborating with Marcia as we support 908 Devices in executing on its vision to democratize mass spectrometry.
  • This press release includes forward looking statements, including with respect to the composition of the Companys Board of Directors.

Global Esoteric Testing Market Report to 2024 - Trends, Forecast, and Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Other Science, Science, Skills, Market research, Burlington, North Carolina, LabCorp, Test market, Medical laboratory, Invitae, Articles, Branches of biology

b'The "Esoteric Testing Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com\'s offering.\nThe future of the esoteric testing market looks promising with opportunities in the independent & reference laboratories and hospital laboratories industries.

Key Points: 
  • b'The "Esoteric Testing Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com\'s offering.\nThe future of the esoteric testing market looks promising with opportunities in the independent & reference laboratories and hospital laboratories industries.
  • The global esoteric testing market is expected to grow with a CAGR of 12% from 2019 to 2024.
  • To learn the scope of, benefits, companies researched and other details of the esoteric testing market, then read this report.\nThe study includes the esoteric testing market size and forecast for the global esoteric testing market through 2024, segmented by product type, technology, end user, and region.\nSome of the esoteric testing companies profiled in this report include Labcorp, Quest Diagnostics, Opko Health, Miraca, Myriad Genetics, Sonic Healthcare, Foundation Medicine, ACM Global Laboratories, Arup Laboratories, Fulgent Genetics, Invitae, Mayo Medical Laboratories, and Spectra Laboratories.\nSome of the features of \'Global Esoteric Testing Market 2019-2024: Trends, Forecast, and Opportunity Analysis\' include:\nMarket size estimates: Global esoteric testing market size estimation in terms of value ($M) shipment.\nTrend and forecast analysis: Market trend (2013-2018) and forecast (2019-2024) by segments and region.\nSegmentation analysis: Global market size by product type, technology, end user, and region.\nRegional analysis: Global esoteric testing market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.\nGrowth opportunities: Analysis on growth opportunities in different applications and regions for esoteric testing in the global esoteric testing market.\nStrategic analysis: This includes M&A, new product development, and competitive landscape for, esoteric testing in the global esoteric testing market.\nAnalysis of competitive intensity of the industry based on Porter\'s Five Forces model.\nThis report answers the following 11 key questions:\nWhat are some of the most promising potential, high-growth opportunities for the global esoteric testing market by product type, technology, end user and region (North America, Europe, Asia-Pacific, and ROW)?\nWhich segments will grow at a faster pace and why?\nWhich regions will grow at a faster pace and why?\nWhat are the key factors affecting market dynamics?
  • What are the drivers and challenges of the esoteric testing market?\nWhat are the business risks and threats to the esoteric testing market?\nWhat are emerging trends in this esoteric testing market and the reasons behind them?\nWhat are some changing demands of customers in the esoteric testing market?\nWhat are the new developments in the esoteric testing market?

The Access to Comprehensive Genomic Profiling Coalition Adds New Member

Retrieved on: 
Thursday, May 20, 2021
Life sciences, Medical genetics, Branches of biology, Biology, Burlington, North Carolina, LabCorp, Molecular diagnostics, Mayo Clinic, Exact Sciences

b'WASHINGTON, May 20, 2021 /PRNewswire/ --The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Mayo Clinic Laboratories to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.\n"On behalf of ACGP, we welcome Mayo Clinic Laboratories to the coalition working to advocate for access to comprehensive genomic profiling (CGP) for patients living with advanced cancer," said Jim Almas, MD, vice president and national medical director of clinical effectiveness at Labcorp, and chairman of ACGP.

Key Points: 
  • b'WASHINGTON, May 20, 2021 /PRNewswire/ --The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Mayo Clinic Laboratories to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.\n"On behalf of ACGP, we welcome Mayo Clinic Laboratories to the coalition working to advocate for access to comprehensive genomic profiling (CGP) for patients living with advanced cancer," said Jim Almas, MD, vice president and national medical director of clinical effectiveness at Labcorp, and chairman of ACGP.
  • "The addition of Mayo Clinic Laboratories, a recognized global reference laboratory that supports patient care and access to specialized testing, is further evidence of growing stakeholder interest in improving access to CGP.
  • "\nCGP testing performed soon after a diagnosis of advanced cancer better informs medical management, including treatment decisions and patient care, which can improve clinical outcomes.
  • If you are interested in learning more about becoming a member, please contact us here .\nAccess to Comprehensive Genomic Profiling (ACGP) is a collaborative coalition of leading molecular diagnostics companies and laboratories that aims to raise awareness about comprehensive genomic profiling (CGP) for advanced cancer patients.\n'

Labcorp to Speak at UBS Global Healthcare Virtual Conference

Retrieved on: 
Tuesday, May 18, 2021
Research, Hospitals, Clinical trials, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Burlington, North Carolina, LabCorp, New York Stock Exchange, Economy of New York City, Companies

Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives.

Key Points: 
  • Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives.
  • With more than 70,000 employees, we serve clients in more than 100 countries.
  • Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020.
  • All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Pixel by Labcorp COVID-19 PCR Test Home Collection Kit Receives FDA Emergency Authorization for Ages 2-17

Retrieved on: 
Thursday, May 13, 2021
Children, Biotechnology, FDA, Managed care, Health, Research, Infectious diseases, Family, Hospitals, Consumer, Science, Life sciences, Articles, Burlington, North Carolina, LabCorp, Biology, Biotechnology, Molecular biology, Laboratory techniques, Polymerase chain reaction, Emergency Use Authorization

b'Labcorp (NYSE: LH), a leading global life sciences company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit for ages 2-17.

Key Points: 
  • b'Labcorp (NYSE: LH), a leading global life sciences company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit for ages 2-17.
  • \xe2\x80\x9cThis is welcome news as children and parents look forward to summer activities, camps, travel and the upcoming school year.\xe2\x80\x9d\nPixel by Labcorp COVID-19 PCR Home Collection Kit uses the same PCR test trusted by doctors and hospitals across the country.
  • Once the request is received by Labcorp, a kit will be shipped to the individual\xe2\x80\x99s home via FedEx.
  • For adults 18 and over, the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit is also available in over 6,000 pharmacies nationwide.\nLabcorp offers its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit for zero upfront costs when clinical guidelines are met.